The Readout LOUD By Adam Feuerstein and Meg Tirrell Listen: What’s next for Roche, a debate over second boosters, & Vertex’s recent success
First Opinion By Alina Bills Turning to social media to get affordable insulin: a clear sign of a broken health care system
First Opinion By Gary Taubes How a ‘fatally, tragically flawed’ paradigm has derailed the science of obesity
STAT Madness By Rebecca Sohn Researchers pursuing novel treatments for herpes infections and diabetes win STAT Madness
Health By Elizabeth Cooney People with type 1 diabetes have a higher risk of dying from Covid-19. Why are they lower on CDC’s vaccine priority list?
Health By Nicholas Florko See one woman’s complicated, costly journey to a Canadian strip mall pharmacy — all for cheaper insulin
First Opinion By John LaMattina Today’s insulin isn’t what Banting and Best developed. It’s far, far better
Politics By Nicholas Florko Human Rights Watch says unaffordable U.S. insulin is a human rights abuse
Exclusive By Matthew Herper Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments
First Opinion Podcast By Patrick Skerrett Listen: The ‘underground market’ for insulin and diabetes supplies
Pharmalot By Ed Silverman Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work?
Pharmalot By Ed Silverman Michigan attorney general pursues investigation into Lilly’s ‘grossly’ excessive insulin prices
Health Tech By Katie Palmer Medicine’s first autonomous AI could prevent blindness due to diabetes — if it can reach those most in need
Health Tech By Katie Palmer Carbon Health launches a program for continuous glucose monitoring to curb diabetes risk
Pharmalot By Ed Silverman Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited
Health By Elizabeth Cooney As diabetes prevalence rises in children and adults, screening age drops to 35 for overweight adults
Health Tech By Katie Palmer Artificial pancreases were a breakthrough for type 1 diabetes. The research in type 2 is just beginning
Pharmalot By Ed Silverman Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit
Health Tech By Katie Palmer Demand is growing for continuous glucose monitoring for type 2 diabetes. Primary care doctors need to prepare
Pharmalot By Ed Silverman ‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism
Exclusive By Erin Brodwin Onduo’s new exec on Google’s data skills, real-world evidence, and moving the needle on outcomes
Exclusive By Erin Brodwin Carbon Health dives into digital diabetes care with virtual clinic acquisition
Health Tech By Elizabeth Cooney Measuring blood sugar in real time is a game changer for patients — and a health tech success story
Health Tech By Katie Palmer Glucose monitors revolutionized diabetes care. Now digital health startups want to bring them to the masses
Pharmalot By Ed Silverman Congressional lawmakers urge FTC to investigate insulin makers over their pricing
Pharmalot By Ed Silverman Insulin makers win a significant round in Minnesota lawsuit accusing them of racketeering